{"filing":{"accession_number":"0001833141-26-000058","cik":"0001833141","ticker":"HELP","company_name":"CYBIN INC.","form":"6-K","filing_date":"2026-08-14","report_date":"2026-08-14","primary_document":"cybininc-form6xkq12027.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1833141/000183314126000058/cybininc-form6xkq12027.htm"},"events":[{"id":27734,"run_id":25309,"accession_number":"0001833141-26-000058","anchor_item_number":"EX-99.5","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"This is a press release announcing first quarter fiscal 2027 financial results for Helus Pharma (Cybin Inc.), including cash position ($166.4 million), net loss ($47.8 million), and operating expenses ($37.5 million) for the quarter ended June 30, 2026. The document explicitly states \"Helus Pharma Reports First Quarter Fiscal 2027 Financial Results\" and includes financial highlights typical of an earnings release. While the release also discusses business milestones (CEO appointment, clinical trial progress), the primary disclosure is the quarterly financial results, making this an earnings_release rather than a periodic report.","company_name":"CYBIN INC.","ticker":"HELP","filing_date":"2026-08-14","form":"6-K","submitted_at":null,"items":[{"id":29394,"accession_number":"0001833141-26-000058","item_number":"EX-99.5","item_title":"q12027financialresultspres.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This is a press release announcing first quarter fiscal 2027 financial results for Helus Pharma (Cybin Inc.), including cash position ($166.4 million), net loss ($47.8 million), and operating expenses ($37.5 million) for the quarter ended June 30, 2026. The document explicitly states \"Helus Pharma Reports First Quarter Fiscal 2027 Financial Results\" and includes financial highlights typical of an earnings release. While the release also discusses business milestones (CEO appointment, clinical trial progress), the primary disclosure is the quarterly financial results, making this an earnings_release rather than a periodic report.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-14T11:46:49.453502+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29390,"accession_number":"0001833141-26-000058","item_number":"EX-99.1","item_title":"cybin-financialstatementsx.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This exhibit is a condensed interim consolidated financial statement for the three-month period ended June 30, 2026, prepared in accordance with IAS 34 Interim Financial Reporting. The document explicitly states it is \"unaudited\" and should be read in conjunction with the annual financial statements for the year ended March 31, 2026. This is a periodic interim financial report, not a discrete event or earnings release announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-14T11:46:49.453502+00:00","company_name":"CYBIN INC.","ticker":"HELP","filing_date":"2026-08-14"},{"id":29391,"accession_number":"0001833141-26-000058","item_number":"EX-99.2","item_title":"cybin-mdaxq1x27.htm","event_type":"periodic_quarterly","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This exhibit is a Management's Discussion and Analysis (MD\u0026A) for the three months ended June 30, 2026, filed as part of a 6-K on August 14, 2026. The document explicitly states it is prepared \"in conjunction with Helus Pharma's unaudited condensed interim consolidated financial statements and notes for the three months ended June 30, 2026.\" This is a periodic interim financial report covering a quarterly period, not a discrete event or earnings release announcement. MD\u0026As accompanying quarterly financial statements are classified as periodic_quarterly filings that are deferred for separate processing.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-14T11:46:49.453502+00:00","company_name":"CYBIN INC.","ticker":"HELP","filing_date":"2026-08-14"},{"id":29392,"accession_number":"0001833141-26-000058","item_number":"EX-99.3","item_title":"q12027-cybinceocertificate.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This is a Form 52-109F2 CEO certification of interim filings for the period ended June 30, 2026. The certificate certifies the interim financial statements and interim MD\u0026A, which are periodic interim financial reports. The certification itself is a routine administrative disclosure required under Canadian securities law (National Instrument 52-109) and does not constitute a discrete material event; it accompanies the underlying interim financial report, which should be classified as periodic_interim.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-14T11:46:49.453502+00:00","company_name":"CYBIN INC.","ticker":"HELP","filing_date":"2026-08-14"},{"id":29393,"accession_number":"0001833141-26-000058","item_number":"EX-99.4","item_title":"q12027-cybincfocertificate.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This is a Form 52-109F2 certification of interim filings by the CFO for the interim period ended June 30, 2026. The document certifies the interim financial statements and MD\u0026A, not a discrete event. It is a routine compliance certification accompanying a periodic interim financial report, not a material event disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-14T11:46:49.453502+00:00","company_name":"CYBIN INC.","ticker":"HELP","filing_date":"2026-08-14"},{"id":29394,"accession_number":"0001833141-26-000058","item_number":"EX-99.5","item_title":"q12027financialresultspres.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This is a press release announcing first quarter fiscal 2027 financial results for Helus Pharma (Cybin Inc.), including cash position ($166.4 million), net loss ($47.8 million), and operating expenses ($37.5 million) for the quarter ended June 30, 2026. The document explicitly states \"Helus Pharma Reports First Quarter Fiscal 2027 Financial Results\" and includes financial highlights typical of an earnings release. While the release also discusses business milestones (CEO appointment, clinical trial progress), the primary disclosure is the quarterly financial results, making this an earnings_release rather than a periodic report.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-14T11:46:49.453502+00:00","company_name":"CYBIN INC.","ticker":"HELP","filing_date":"2026-08-14"}]}